These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 35910989)

  • 21. A double-edged sword: The effects of R&D intensity and capitalization on institutional investment in entrepreneurial firms.
    Feng Y; Ma C; Wang Y; Ma J
    Front Psychol; 2022; 13():942931. PubMed ID: 36211902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does chief executive officer turnover affect green innovation quality and quantity? Evidence from China's manufacturing enterprises.
    Zhang Y; Liu H; Li M
    Environ Sci Pollut Res Int; 2023 Jul; 30(34):81760-81782. PubMed ID: 35499719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How does CEO narcissism affect enterprise ambidextrous technological innovation? The mediating role of corporate social responsibility.
    Wang Z; Hu X; Yu F
    PLoS One; 2023; 18(1):e0280758. PubMed ID: 36662757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Executive Overconfidence, Digital Transformation and Environmental Innovation: The Role of Moderated Mediator.
    Zhou P; Zhou S; Zhang M; Miao S
    Int J Environ Res Public Health; 2022 May; 19(10):. PubMed ID: 35627526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Power of Unrequited Love: The Parasocial Relationship, Trust, and Organizational Identification Between Middle-Level Managers and CEOs.
    Liao Y; Lin B; Zhou H; Yang X
    Front Psychol; 2021; 12():689511. PubMed ID: 34566768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of economic policy uncertainty on firms' investment in innovation: Evidence from Chinese listed firms.
    Kun W; Hu X; Liu F
    PLoS One; 2022; 17(11):e0272983. PubMed ID: 36378624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Mechanisms of Chief Executive Officer Characteristics and Corporate Social Responsibility Reporting: Evidence From Chinese-Listed Firms.
    Zhao X; Wang M; Zhan X; Liu Y
    Front Psychol; 2022; 13():794258. PubMed ID: 35401325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Key Subordinate Executive Governance, CEO Overconfidence, and Accounting Conservatism: From the Perspective of Sustainable Development.
    Wu F; Kuang X
    Front Psychol; 2021; 12():799221. PubMed ID: 35185696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic Policy Uncertainty and Family Firm Innovation: Evidence From Listed Companies in China.
    Qi Y; Dong S; Lyu S; Yang S
    Front Psychol; 2022; 13():901051. PubMed ID: 35774937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CEO turnover and corporate innovation: What can we learn from Chinese listed companies.
    Sun S; Jiang H
    Front Psychol; 2022; 13():874907. PubMed ID: 35936347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Automation, organizational ambidexterity and the stability of employee relations: new tensions arising between corporate entrepreneurship, innovation management and stakeholder management.
    Hiebl MRW; Pielsticker DI
    J Technol Transf; 2023 Feb; ():1-29. PubMed ID: 36816884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Will the Volume-Based Procurement Policy Promote Pharmaceutical Firms' R&D Investment in China? An Event Study Approach.
    Hu Y; Chen S; Qiu F; Chen P; Chen S
    Int J Environ Res Public Health; 2021 Nov; 18(22):. PubMed ID: 34831803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Celebrity CEOs and firm innovation investment: Evidence from Chinese-listed companies.
    Shao D; Lv K; Zhao S; Wang S
    Front Psychol; 2022; 13():978946. PubMed ID: 36478933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Executive pharmaceutical background, R&D investment and corporate innovation performance.
    Zhang L; Li S; Wu M
    Am J Transl Res; 2023; 15(11):6576-6586. PubMed ID: 38074834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CEO successor origins, top management team faultline, and strategic change-empirical evidence from China.
    Ren D; Jiang H; Cheng J; Peng C; Zou Y
    Heliyon; 2023 Sep; 9(9):e19200. PubMed ID: 37662732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behavioural Phenomena of Family Firm Control Diversity and R&D Investment with Moderating Role CEO Compensation.
    Ghafoor S; Zulfiqar M; Wang M; Wang C; Islam MR
    Psychol Res Behav Manag; 2023; 16():397-417. PubMed ID: 36819007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CEO busyness and firm performance: evidence from Indonesia.
    Harymawan I; Nasih M; Ratri MC; Nowland J
    Heliyon; 2019 May; 5(5):e01601. PubMed ID: 31193196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Curvilinear Relationships Between Top Decision Maker Goal Orientations and Firm Ambidexterity: Moderating Effect of Role Experience.
    Pryor C; Santos SC; Xie J
    Front Psychol; 2021; 12():621688. PubMed ID: 33935873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can R&D investment reduce the impact of COVID-19 on firm performance?-Evidence from India.
    Biswas S
    J Public Aff; 2021 Oct; ():e2773. PubMed ID: 34899063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Female CEO succession and corporate social disclosure in China: unveiling the significance of ownership status and firm performance.
    Shaheen R; Luo Q; Bala H
    Environ Sci Pollut Res Int; 2023 Feb; 30(6):14223-14239. PubMed ID: 36149559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.